Clarity Pharmaceuticals (ASX:CU6) said a prospective, investigator-initiated, phase 2 imaging trial seeking to compare the detection rate of sites of prostate cancer recurrence as determined by the number of lesions per patient, between two agents, completed enrollment, and all participants were imaged, according to a Thursday Australian bourse filing.
The study is evaluating the performance of copper-64 SAR-bisPSMA in comparison with the standard-of-care gallium-68-PSMA-11 for the detection of prostate cancer recurrence in patients with low prostate-specific antigen (PSA), who are candidates for curative salvage therapy.
Eligible patients were required to have had a radical prostatectomy with no salvage therapy and a PSA of between 0.2 nanograms per milliliter and 0.75 ng/mL.
The drugmaker's shares rose past 3% in recent trading on Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。